Skip to content

DEBuT-LRP study: Intravascular Identification and Drug-Eluting Balloon Treatment of Vulnerable Lipid-Rich Plaques

DEBuT-LRP study: Intravascular Identification and Drug-Eluting Balloon Treatment of Vulnerable Lipid-Rich Plaques - DEBuT-LRP

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON54017
Enrollment
50
Registered
2020-12-21
Start date
2021-01-19
Completion date
Unknown
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myocardial infarction

Interventions

DEB-treatment of LRP, as detected with IVUS/NIRS

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Patient has an acute coronary syndrome without ST-segment elevation on the ECG (NSTE-ACS), includingnon-ST-elevation myocardial infarction and unstable angina pectoris. 2. An invasive revascularization strategy for NSTE-ACS with PCI is chosen.

Exclusion criteria

Exclusion criteria: Angiographic exclusion criteria: 1. Previous coronary artery bypass-grafting; 2. A chronic total occlusion is present; 3. Too many (complex) coronary lesions requiring staged PCI procedure(s); 4. Procedural complication of the index PCI; Clinical exclusion criteria: 5. Unstable patients (the presence of cardiogenic shock, need for intubation, need for inotropes); 6. Patients with ST-segment elevations on the ECG requiring immediate primary PCI; 7. Body weight > 250 kg; 8. Known renal insufficiency (estimated Glomerular Filtration Rate [eGFR]

Design outcomes

Primary

MeasureTime frame
The difference in LCBImm4 between baseline and 9 months in DEB-treated LRPs

Secondary

MeasureTime frame
• The change in lipid-core burden index in a 4 mm segment (LCBImm4) as measured with IVUS + NIRS from baseline to 9 month follow-up in identified additional LRPs that are not treated with DEB. • Flow-limiting dissection necessitating bail-out stent implantation; • Periprocedural myocardial infarction; • LRP lesion failure, defined as cardiac death, myocardial infarction, or ischemia-driven revascularization related to an identified non-culprit LRP lesion up to one-year follow-up; • Patient-oriented composite outcomes, defined as all-cause mortality, myocardial infarction, or any repeat revascularization up to one-year follow-up; • Additional IVUS + NIRS lesion characteristics (plaque volume, minimal lumen area).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)